Establishment of an animal model of hepatic encephalopathy

Chinese Medical Journal (Taipei)

Volumn 63, Issue 4, 2000, Pages 263-269

  Chu, Chi Jen ^a   Lee, Fa Yauh ^a   Wang, Sun Sang ^a   Chang, Full Young ^a   Lin, Han Chieh ^a   Wu, Shwu Ling ^a   Chan, Che Chang ^a   Tsai, Yang Te ^b   Lee, Shou Dong ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Animal model; Hepatic encephalopathy; Motor activity; Neurobehavioral testing; Thioacetamide

Indexed keywords

SODIUM CHLORIDE; THIOACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CIRCADIAN RHYTHM; CONTROLLED STUDY; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; LIVER CELL DAMAGE; LIVER FAILURE; MALE; MOTOR ACTIVITY; NEUROLOGIC EXAMINATION; NONHUMAN; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; HEPATIC ENCEPHALOPATHY; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; THIOACETAMIDE;

EID: 0034022863     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gammal SH, Jones EA. Hepatic encephalopathy. Med Clin North Am 1989;73:793-813.
2. Jones DB. Hepatic encephalopathy. J Gastroenterol Hepatol 1993;8:363-9.
3. Sherlock S. Fulminant hepatic failure. Adv Intern Med 1993;38:245-67.
4. Wong F, Blendis LM. Ascites and portal-systemic encephalopathy as complications of cirrhosis. Curr Opin Gastroenterol 1993;9:391-6.
5. Mousseau DD, Butterworth RF. Current theories on the pathogenesis of hepatic encephalopathy. Soc Exp Biol Med 1994;206:329-44.
6. Terblanche J, Hickman R. Animal models of fulminant hepatic failure. Dig Dis Sci 1991;36:770-4.
7. Albrecht J, Hilgier W, Rafalowska U. Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptive response? J Neurosci Res 1990;25:125-30.
8. 3H]-deoxyglucose. Acta Neurol Scand 1991;83: 353-5.
9. Osada J, Aylagas H, Miro-Obradors MJ, Arce C, Palacios-Alaiz E, Cascales M. Effect of acute thioacetamide administration on brain phospholipid metabolism. Neurochem Res 1990;15:927-31.
10. Yurdaydin C, Hortnagl H, Stiendl P, Zimmermann C, Pifl C, Singer EA, et al. Increased serotonergic and nonadrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. Hepatology 1990; 12:695-700.
11. Zimmermann C, Ferenci P, Pifl C, Yurdaydin C, Ebner J, Lassmann H, et al. Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acidergic neurotransmission. Hepatology 1989;9:594-601.
12. A-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 1991;14:963-8.
13. Bengtsson F, Gage FH, Jeppsson B, Nobin A, Rosengren E. Brain monoamine metabolism and behaviour in portacaval shunted rats. Exp Neurol 1985:90:21-35.
14. Bengtsson F, Nobin A, Falck B, Gage FH, Jeppsson B. Portacaval shunt in the rat: selective alternations in behaviour and brain serotonin. Pharmacol Biochem Behav 1986; 24:1611-6.
15. Bengtsson F, Bugge M, Brun A, Falck B, Henriksen KG, Nobin A. The impact of time after portacaval shunt in the rat on behaviour, brain serotonin and brain and muscle histology. J Neurol Sci 1988;83:109-22.
16. Ribeiro J, Nordlinger B, Ballet F, Cynober L, Coudray-Lucas C, Baudrimont M, et al. Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy in portacaval-shunted rats. Hepatology 1992;15:12-8.
17. Conjeevaram HS, Nagle A, Katz A, Kaminsky-Russ K, McCullough AJ, Mullen KD. Reversal of behavior changes in rats subjected to portacaval shunt with oral neomycin therapy. Hepatology 1994;19:1245-50.
18. Gammal S, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology 1990;11:371-8.
19. Hunter AL, Holscher MA, Neal RA. Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 1977; 200:439-48.
20. Mori W, Aoyama H. Statistical study on fulminant liver disease in Japan. Appl Pathol 1983;1:209-22.
21. Porter WR, Gudzinowicz MJ, Neal RA. Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. J Pharmacol Exp Ther 1979;208:386-91.
22. Zaki AEO, Ede RJ, Davis M, Williams R. Experimental studies of blood brain barrier permeability in acute hepatic failure. Hepatology 1984;4:359-63.
23. Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986;3:75-82.
24. Rehnström J, Simert G, Hansson JA, Johnsson G, Vang J. Chronic hepatic encephalopathy. A psychometrical study. Scand J Gastroenterol 1977;12:305-11.
25. Rikkers L, Jenko P, Rudman D, Freides D. Subclinical hepatic encephalopathy: detection, prevalence and relationship to nitrogen metabolism. Gastroenterology 1978; 75:462-9.
26. 4 cirrhosis of rats. Hepatology 1989;9:373-9.
27. 4 in rats. Toxicol Appl Pharmacol 1987;91:461-8.
28. 4 in rats. Toxicology 1990;61:241-7.
29. Wilder P, Fisch HU, Schoch P, Zimmermann A, Schlapfer TE, Reichen J. Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat. Hepatology 1993;18:1459-64.